Logo

Exclusive Webinar: Deal And Venture Trends Through The First Half Of 2020

Share this

Exclusive Webinar: Deal And Venture Trends Through The First Half Of 2020

On September 2, 2020, Octavus Consulting and DealForma will present their most recent data and trends on dealmaking across biopharma, device, diagnostics, and digital health. Healthcare and life sciences deal and venture activity through August 2020 has not slowed down despite the challenges thrown at business leaders globally.

We will review recent trends covering the following:

  • R&D Partnerships by the Numbers Deal Values and Activity
  • M&A among Biopharma, Device, Diagnostics, and Digital Health Companies
  • Venture Investments into Companies by Therapy Area and Technology
  • Top 20 Deals signed through August 2020

Our Presenters

Aditya Singh

Principal Consultant, Octavus Consulting

Chris Dokomajilar

CEO, DealForma

 

REGISTER NOW

About Octavus Consulting:

Octavus is a boutique consulting company, engaged in comprehensive business research, market intelligence, market research and data analytics by providing support and outsourcing solutions to bio-pharma, medtech, diagnostics, digital health companies and healthcare start-ups.

About Dealforma:

DealForma helps biopharma business development analysts be better at industry research by providing them clean information and direct analyst support. Business development teams use the DealForma platform to prepare for partnering meetings, research deals, funding trends, technologies, products, and the therapeutic areas they care about. We built DealForma to provide high quality, comprehensive data from thousands of companies and industry sources all in carefully curated profiles in an easy-to-use interface.


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions